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Abstract 
Purpose:  The prevalence of diabetes (DM) is increasing globally with type 2 
diabetes (T2DM) being primarily responsible for this alarming trend. Age and DM 
have been associated with an increased prevalence of AR cataract in earlier studies 
but T2DM has not been considered separately from type 1 diabetes. Furthermore, 
study results have been inconsistent in terms of whether nuclear sclerosis (NS), 
cortical cataract (CC) or posterior subcapsular (PSC) are specifically associated with 
DM. The purpose of this thesis was to provide Canadian data on these issues while 
considering the limitations found in earlier studies in terms of variable age group 
selection and cataract definition. Logistic regression analysis was extended beyond 
risk analysis to model the prevalence of AR cataract across the human age range. 
Finally, as statins are commonly prescribed for patients with T2DM, the impact of 
using this pharmaceutical on AR cataract prevalence was investigated.  
Methods:  A file review of over 6397 clinic files was performed to create the 
Waterloo Eye Study (WatES) database. Abstracted data included patient age and sex, 
the presence of early to late AR cataract (NS, CC, PSC or related lens extraction-
LE), systemic health diagnoses including a diagnosis of T2DM or type 1 diabetes, 
and any medication used. Data quality was looked at through repeatability with 
double-entry of files and calculation of missing data rates. Comparisons were done 
between the study population demographics (age and sex) and those available on the 
general population and representative Canadian optometric patients. Prevalence of 
AR cataract was determined for the entire study group and for yearly age-groups. 
The probability of AR cataract generated from logistic regression analysis was used 
to model the prevalence of AR cataract over the entire age range of patients. Similar 
functions were determined for T2DM and non-diabetic (ND) subgroups and then 
again after further subdividing them into patients who did and did not use statins. 
The age of 50% prevalence of AR cataract were determined for each of these 
functions. Distribution rates of mixed and uniform cataract were calculated and 
compared for the T2DM and ND subgroups. Age of first lens extraction and 
differences in LE rates were also determined for these groups. Multivariable logistic 
 iv 
regression analysis was done to determine odds ratios (OR) for associations between 
variables (patient age, being female, having a diagnosis of T2DM, smoking, systemic 
hypertension, and statin use) and the outcome of AR cataracts or its subtypes.     
Results: Data abstraction repeatability was found to be high and missing data rates 
were found to be low. While significant differences existed between the 
demographics of the general population and this clinic population, the sex and age 
distributions were comparable to optometric practices in Canada. The overall 
prevalence of AR cataract, NS, CC,and PSC in this population was 35.3%, 28.8%, 
9.9%, and 3.6% respectively. The yearly prevalence of AR cataract in this population 
was found to increase in a sigmoid trend over the course of the human age span that 
began to rise after 38 years of age and approached 100% by 75 years of age.  When 
modelled into a probability of cataract function, 50% prevalence of AR cataract 
occurred at 56.6 years of age. T2DM was reported in 452 WatES patients; 97% of 
whom were over 38 years of age.  The probability of 50% AR cataract, NS, and CC 
prevalence occurred almost four years earlier in the T2DM subgroup compared to 
those without diabetes. PSC was much less prevalent and did not reach 50% levels, 
but the age of 10% prevalence was eight year earlier in the T2DM group compared 
to the ND group. Patients with T2DM had more mixed cataract, a higher rate of LE 
and an earlier age of first LE than non-diabetics. Statin use was reported in 761 
patients; 96% who were over 38 years of age. Statin use was 3.5 times more common 
in patients with T2DM compared to non-diabetics. When the diabetic subgroups 
were further subdivided by those who do and do not use statins, the age of 50% 
probability of AR cataracts was now almost eight years earlier in the T2DM patients 
using statins compared to the ND patients who did not. The probability functions 
were similar between T2DM patients not using statins and ND patients who did 
report statin use. Having a diagnosis of T2DM was significantly associated with 
early to late NS and CC when controlling for statin use, whereas statin use was 
significantly associated with NS and PSC when controlling for a diagnosis of T2DM. 
Conclusions:  AR cataract, T2DM and statin use were prevalent conditions in this 
clinic population, especially over 38 years of age. Modelling the prevalence of AR 
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cataract over a broad age range could assist predicting cataract in Canadian 
optometric patients. A diagnosis of T2DM resulted in an earlier development of all 
three cataract subtypes, resulting in increased rates of LE and mixed cataract. 
However, the association was only significant for NS and CC when controlling for 
statin use. Given the frequent use of statins in patients with T2DM, the significant 
association found between statin use and increased risk of AR cataract warrants 
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Chapter 1  
Introduction and literature summary 
 
1.1 Type 2 diabetes 
Diabetes mellitus (DM) is a chronic metabolic disease involving hyperglycemia.
1,2
 
The Institute for Clinical Evaluative Sciences (ICES) reports that as of 2003, over 2 
million Canadians had DM at a estimated cost to healthcare of over $9 billion 
annually.
3
 The prevalence of the disease has been increasing worldwide such that it 





 Traditionally, diabetes is diagnosed by a fasting blood plasma 
glucose level of   126 mg/dL or less commonly, a two hour plasma glucose level of  







from studies on the associated risk of  microvascular changes, namely retinopathy.
5
  
A glycosylated hemoglobin (Hgb A1C) level of   6.5% is also suggestive for  
diagnosis if repeatable or found in combination with hyperglycemic symptoms (e.g. 
polyuria, polydipsia, weight loss),  as is a casual plasma glucose of   200mg/dL if 
hyperglycemic symptoms exist.
1
 Glycosylated hemoglobin levels indicate the 
amount of glucose a red blood cell has been exposed to over the previous 120 days.  
The goal of diabetic therapy is an A1C of 7% or less.
5
 Impaired fasting glucose (100 
to 125 mg/dL) and impaired glucose tolerance (140 to 199 mg/dL) are identified as 
transitional stages in the progression towards DM.
1,5 
  Type 2 diabetes (T2DM) accounts for approximately 90% of all cases of DM.
1,5
  It 




facilitates the entry of glucose into cells and inhibits the release of glucose from the 
liver. Insulin resistance in T2DM affects both of these mechanisms.
5
 As insulin and 
blood sugar levels rise, kidney function is altered resulting in lipid abnormalities 
including increased triglycerides.
2  
Exogenous  insulin is only required for treatment 
of  T2DM when blood glucose levels cannot be adequately controlled with dietary 
changes, increased activity levels, and/or oral hypoglycemic agents.
1
  T2DM is 
thought to be the result of genetic predisposition and lifestyle choices as age, obesity 
and family history are significant risk factors.  Unfortunately, there has been a shift 





1.2 Type 2 Diabetes and use of statins 
Metabolic syndrome is a combination of medical disorders that occur together and 
increase the risk of cardiovascular disease and T2DM.  The requirements for 
diagnosis vary somewhat among health groups but most often include central 
obesity, hypertension, dyslipidemia, and insulin resistance.
5,6
  The Centre for Disease 
Control and Prevention in the USA estimated the age-adjusted prevalence of 
metabolic syndrome to be 23.7% in their large nationally representative sample over 
20 years of age.
 6
 As a result, many patients with T2DM have concurrent high blood 
pressure, lipid abnormalities and increased risk of stroke or coronary arteryhe 
disease.
5,7   
Statins are one of the most widely prescribed drugs worldwide.
8
  Introduced in the 
early 1980’s, this pharmaceutical group of 3-hydroxy-3-methyl-glutaryl-CoA 
 3 
reductase inhibitors can lower low-density lipoprotein (LDL) cholesterol in those 
with pre-existing cardio-vascular disease (CVD) or at high risk of heart disease. 
Neutel et al reported that between 1994 and 2002, overall age-adjusted statin use in 
Canada increased from 1.6% to 7.8%.
9
 The main atherogenic components in patients 
with T2DM include a preponderance of small, dense LDL’s, elevation in tri-
glyceride-rich lipoprotein particles and low high-density (HDL) levels. Lowering 
LDL levels is considered the first priority in cholesterol control in T2DM.
10
 
Recognizing the risks of dyslipidemia in patients with T2DM, studies were 
conducted to look at the benefit of statin use in patients with T2DM.  For example, 
the Collaborative Atorvastatin Diabetes Study (CARDS) (2004)
 11
 was a multicentre 
randomised placebo-controlled trial in the UK looking at the role of statins for 
primary prevention of CVD in T2DM.  Results involving 2838 patients between 40 
and 75 years of age from their 132 centres were published in 2004. The researched 
concluded that Atorvastatin, significantly reduced the risk of CVD and stroke in 
patients with T2DM even in those without high LDL-cholesterol. They deemed no 
particular LDL threshold was required to recommend statin use for this disease.  The 
trial was halted two years early because the benefit was so overwhelming. Therefore, 
the American College of Physicians is among many groups that advocate the use of 
statins not only for the secondary prevention in patients with coronary artery disease 
and T2DM, but also for primary prevention against macrovascular complications in 
patients with T2DM and any other cardiovascular risk factors.
12 
 
Paradoxically, a recent study has shown that statin therapy is associated with a 
slightly increased risk (9%) of developing incident diabetes (OR= 1.09, 1.02-1.17). 
 4 
The research group performed a meta-analysis on 13 earlier statin trials comprising 
over 91,000 participants.
13
 However, the researchers did not expect this finding to 
change the clinical practice of prescribing statins in patients because the benefit of 
the pharmaceutical agent greatly outweighs the risk.  
 
1.3 Age-related cataract and type 2 diabetes 
Diabetes can affect most ocular tissues and epidemiological studies have shown 
repeatedly that DM is a risk factor for age-related (AR) cataracts.
14, 15, 16, 17
 Some of 
this information has come out of prevalence studies of diabetic retinopathy (DR). 
The Wisconsin Eidemiologic Study of Diabetic Retinopathy
18 
found the severity of 
DR and proteinuria were associated with increased risk of cataract surgery in type 1 
diabetes, whereas age and use of insulin predicted surgical intervention in T2DM. 
Janghorbani et al 
19
, followed 3606 DM patients in Scotland initially free of cataract 
and found that besides age, any retinopathy was a significant independent predictor 
of cataract for both DM types. Additionally, poor metabolic control and duration of 
diabetes were significant independent predictors of cataract in T1D patients.  
Three distinct morphological subtypes of AR cataracts are recognized. Nuclear 
sclerosis (NS), the gradual yellowing of the lens, typically causes reduced acuity, 
color vision change and loss of contrast sensitivity.
20,21  
 Cortical cataracts (CC) start 
as vacuoles or spokes in the lens periphery and cause a gradual decrease in vision, 
glare at night, changes in astigmatism and a risk of monocular diplopia.
20,21  
 




Investigations have varied on which morphological types of age-
related (AR) cataracts are associated with DM but CC and/or PSC have most 
commonly been  linked compared to NS.  The National Health and Nutrition 
Examination Survey (1986) was one of the earlier cross-sectional studies of a large 
population (aged 45-74). The researchers found a significant association between 
DM and PSC. Their definition of cataract was acuity based (6/9).
22
 In 1990, the 
Lens Opacities Case-Control Study (LOCS) attempted to standardize cataract 
grading in studies by introducing comparative lens photographs for evaluation. 
Diabetes in this clinic population was associated with greater than grade one CC 
(OR= 1.98 (1.25, 3.13) and mixed cataract (OR= 1.96 (1.28, 3.00).
14
   Klein et al 
(1998) carried out a five year follow up of the Beaver Dam Eye Study cohort (>42 
years of age) and defined CC and PSC as opacities >5% of the lens surface. They 
found that the use of insulin was associated with CC (OR= 3.3, 95% CI 1.61, 7.08). 
Additionally, increased levels of glycosylated hemoglobin were shown to be 
associated with increased risk of NS (> grade 3 Wisconsin scale) and CC.
23 
The 
Barbados Eye Studies (1998) looked at the relationship between diabetes and the 
prevalence of cataract in their large black population. They reported that a history of 
diabetes was related to cortical cataract only (whether mixed or uniform) in their 
patients, using a definition of grade 2 or greater on the LOCS II scale.  The 
associated risk was higher in their young patients (40 to < 60 yrs.: OR=2.30, 95% CI 
1.63, 3.24) than in their older group (60 to 84 yrs.: OR=1.42, 95% CI 1.03, 1.96).
24
 
At the Barbados Eye Studies four year follow-up (2004), having diabetes increased 
the risk of incident CC (RR= 2.4 (1.8, 3.2) and PSC (RR= 2.9 (1.9, 4.5).
17
 The Pola 
 6 
study (2000) was a cross-sectional study of a large population in France (> 60 years 
of age). Cataract was designated as  2 CC or NS and  1 PSC opacity using the 
LOCSIII system. The investigators found known diabetes of long duration ( 10 
years) had a 2.7 times increased risk of PSC, CC and lens extraction but not NS.
16
 
The Visual Impairment Project looked at the prevalence of age-related cataract in a 
large Australian population (> 40 years of age) and defined cataract as  2 NS 
(Wilmer scale), CC 1/4 of the pupil circumference and PSC  1mm
2
. They found a 
significant association with having diabetes > 5 years and an increased risk of NS 
and CC, but not PSC.
25 
However, at the five year follow up of their cohort, they 
found having diabetes as a significant univariate risk factor for developing PSC only 
(RR, 1.80; 95% CI, 1.10, 3.00).
15
 The Blue Mountains Eye Study (2008) assessed 
their large cohort (49 years of age at baseline) after a ten year period.  Result of 
multivariate analysis indicated that having an impaired fasting glucose level at 
baseline (RR= 3.77; 95% CI, 171, 8.30) or a diagnosis of diabetes (RR= 2.49; 95% 
CI, 1.40, 4.45) was significantly associated with CC, but not other AR types.  
Interestingly, diabetes duration was not associated with incident cataract or 
extraction.
26 
Raman et al (2010) used a cross-sectional study of a clinic population in 
India to look at risk factors for cataracts in patients with diabetes. They found high 
serum triglycerides increased the risk of NS (OR=8.83), poor glycemic control 
increased the risk of CC (OR=2.43) and duration of diabetes increased the risk of 
PSC (OR=1.11).
27 
 Very recently, the Malay Eye Study (2011) found diabetes in 
their 40-80 year old population to be associated with CC (>5% of the lens) 
(OR=2.28, 95%CI, 1.83, 2.83) and any PSC (OR= 1.39, 95% CI, 1.09-1.77).
28
 It is 
 7 
likely that NS, CC and PSC have different pathogenic processes. Identifying any risk 
factors for NS, CC and PSC may help to illuminate the pathogenesis of each cataract 
subtype.
 
The pathogenesis of diabetic age-related lens changes has not been studied in as 
much detail as diabetic retinopathy or neuropathy.  Unlike vascular tissue, the 
crystalline lens is not insulin dependent and instead utilizes anaerobic glucose 
metabolism such as glycolysis and the pentose phosphate pathway.
29
 However, as 
with vascular tissue, an overloading of glucose in these pathways still results in 
sorbitol accumulation and consequential lens cell swelling from osmotic stress. 
Aldose-reductase inhibitors prevent the conversion of glucose to sorbitol, and are 
being investigated as a possible anti-cataract treatment.
30
 Additionally, an increase in 
glycation end products (AGE’s) have also been identified in the cataractous lenses of 
people with diabetes.
29
 Ultrasound evaluation of type 2 diabetic crystalline lenses 
reveals decreased epithelial cell density compared to non-diabetics.
30
 Fiber cells that 
make up the rest of the lens are derived from this single layer of epithelial cells. 
During development, the epithelial cells that grow, and elongate into fiber cells lose 
their nucleus, mitochondria, endoplasmic reticulum and other organelles. As a result, 
the mature lens is completely dependent on the metabolism of this epithelial cell 
layer for transparency.
31
 Fiber cells have a high concentration of soluble proteins, 
primarily crystallins, essential to lens optical properties.
32 
Certain crystallins are 
thought to suppress unfolding and cross-linking of proteins. The oxidative stress and 
AGE’s that occur with diabetes cause insolubilization of these crystallins followed 
by lens opacification.  Recent research has shown unregulated proteolysis of 
 8 
crystallins by calpains, and now calpain inhibitors are being investigated as possible 
way to stop or slow down lens opacification.
32
 Finding therapeutic cataract treatment 
is important as people with diabetes have higher complication rates from lens 
extraction. These include an increased risk of retinopathy acceleration, rubeosis, 





1.4 Age-related cataract, type 2 diabetes and statin use 
Results from epidemiological studies on the relationship between statin use and AR 
cataracts have been inconclusive. Clinical trials on the ocular drug-safety of 
Pravastatin and Simvastatin began to be published around 1990 from Germany, 
Sweden, England and the USA.
33,34,35,36,37,38
 These studies involved sample sizes that 
ranged from less than 20 participants to just over 400 and ranged from 6 months to 3 
year follow up periods.  No evidence was found for pathological lens changes 
induced by the drug treatment. Based on these findings, no adverse side effects on 
the human lens are listed in current drug compendiums and manufacturers do not 
recommend any specific monitoring of the crystalline lens.  And because short-term 
use of statins was not found to be associated with lens opacities in early clinical 
trials, statin-use was generally not a controlled factor in studies on T2DM and its 
associations to AR cataract.  
In contrast to these clinical trials, animal studies have since shown a correlation with 
cataract development with chronic statin treatment.  Cataracts were among the 
 9 
observed changes in beagles caused by fluvastatin at  8mg/kg/day doses for less 
than a year.
39
 Statins have been isolated from the lenses of study dogs (and later 
humans) taking statins indicating the drug does enter its tissues.
40
 Cataractogenic 
activity was also seen in atorvastatin-treated white rats and the drug dose 




One of the earliest observational investigations on cataract and the use of statins was 
a case-control study in UK by Smeeth et al (2003).
42
  There were over 15,000 people 
in both the cataract group and the control group and they were matched for age, sex, 
practice location and observation period.  Looking at an “ever” or “never” criteria for 
statin use, the association between  risk of cataract and statin use did not reach 
significance after a short exposure time (mean = <2 years). Then, Tan et al (2006)
43
 
looked at the risk of incident cataract in their Blue Mountain Eye Study (BMES) 
cohort survivors at five years and ten years post-baseline. Statin use was protective 
for overall cataract (hazard ratio (HR) = 0.52, (95% CI) 0.29-0.93) but there was no 
significant associations for reduced incidence of NS, CC or PSC individually. Their 
definition of cataract was  grade 4 NS on the Wisconsin Cataract Grading System, 
 5% of the total lens surface of CC, or the presence any PSC. However, Smeeth et 
al
42
 point out that incident cataract at these levels is relatively uncommon and that 
many studies involving humans lack adequate power to exlude clinically important 
effects.  In the BMES follow up, out of the 1044 survivors free of AR cataracts at 
baseline, 63 used statins and only 22 of these developed cataracts by the ten-year 
mark. Klein et al (2007)
44
 also looked at the impact of statin use on incident cataract 
 10 
in their Beaver Dam Eye Study cohort at five years post-baseline. Again, they used a 
definition of clinically significant lens opacity for cataract similar to the BMES 
group. No significant difference in incident CC or PSC were found between users of 
statins and non-users in patients free of those opacities at baseline. However, statin-
use was associated with a lower risk of NS (OR= 0.55, (95% CI) 0.36-0.84). There 
were 270 participants who used statins and were free of NS at baseline; 33 of these 
developed NS by the five-year mark. They hypothesized a reduction in oxidative 
stress in the lens with the use of statins for the reduced NS risk.  
Based on the reduced oxidative stress theory, a population-based historical cohort 
study was conducted in Israel between 1998 and 2007on the persistent use of statins 
and incident cataract.  In this investigation, Chodick et al
45
 looked at over 180,00 
new statin users in a large health organization and concluded that persistent statin 
use for this time period was associated with a reduced risk of cataract in participants 
ages 45 to 74 years but paradoxically a higher risk in female participants over 74. No 
explanations for the age-dependent effects were offered. This study depended on a 
diagnosis of AR cataract as recorded by a practitioner in computerized medical 
records without the ability to verify this information. However, Ruigomez et al
46
 had 
previously shown a high degree of validity (94%) for a recorded diagnosis of cataract 
in a large UK medical database compared to an independent consultant in their 
study.   
In contrast, a recent study by Hippisley-Cox and Coupland (2010)
47 
found statin use 
increased the risk of cataract.  This investigation involved a prospective cohort of 
over two million patients in the UK , ages 30-84 from 368 general practices in the 
 11 
QResearch database.  Over 200,000 of the patients were new statin users and Cox 
proportional hazard models were used to estimate effects of statin type, dose and 
duration of use. Based on the 20% threshold for cardiovascular risk, the number to 
harm (NNH) for an additional case of cataract over five years was 33 (95% CI, 28 to 
38).  Interestingly, after stopping statin treatment, the risk of cataract returned to 
normal within a year.  
A very recent case-control study (2011)
48
 looked at the impact of recent statin use on 
cataract surgery rates.  Close to 14,000 patients who had lens extraction were 
compared to over 34,000 controls who were part of a prepaid healthcare community 
in the USA.  After adjusting for age, sex, race, smoking status, diabetes, and 
coronary artery disease, logistic regression analysis showed that statin use of  5 
years or more was protective against cataract surgery in the younger age group (50-
64 yrs.), while shorter-term use of  5 years was associated with an increased risk of 
surgery in both the younger and older age groups ( 59 yrs.). 
There is bio-plausibility for statin use being associated with an increase in AR 
cataracts.  In 1996, Cendella
49
 stated that the human lens contains one of the highest 
cholesterol levels of any known membrane, and that the crystalline lens’ epithelial 
cell layer requires on-site synthesis of cholesterol for proper lens cell development 
and transparency.  Increased cataract formation has been seen in both animals and 
humans with hereditary cholesterol deficiency.
50
 For example, the Smith-Lemli-
Opitz Syndrome is a common inherited human disease that is accompanied by a 
mutated enzyme in the sterol synthetic pathway that converts 7-dehydrocholesterol 
 12 
(7DHC) to cholesterol.  Cholesterol is important in cell membranes, serves as the 
precursor for steroid hormones and bile acids, and is a major component in myelin.
51
 
Commonly, fetuses with Smith-Lemli-Opitz syndrome abort spontaneously, but for 
those who survive, cataracts can acutely occur in the postnatal period.
52
 Statins 
inhibit an early enzyme of cholesterol production and the risk exists that statins can 
inhibit cholesterol biosynthesis in the human lens.
49
  Once a patient has been 
prescribed a statin, these drugs are generally intended for life-long use.
50
 Cenedella 
suggests that the impact of statin use requires study periods of between10 to 20 years 
due to the slow life-long growth of the lens.
49
  Beri et al. published a literature 
review of studies between 1950 and 2008 involving the non-arteroprotective effects 
of statins. They concluded there was inadequate and conflicting evidence for statin 




Up to now, most studies on the risk factors for AR cataract have involved DM but it 
is also important to consider T2DM separate from type 1 diabetes as the 
epidemiological trends of the two processes are different. Also, little work has been 
done specifically on the wide use of statins in patients with T2DM and their 
combined impact on cataract development.  Recently, Hermans and Rousseau 
(2011)
54
 did a cross-sectional analysis of 780 T2DM outpatients in Belgium. After 
equalizing groups for mean age, statin type and diabetes duration, overall cataract 
prevalence was not significantly higher in statin users versus non-users. Analysis 
involved the Fisher’s exact test for differences in proportions. What remains to be 
investigated is the impact of statins on cataract development, utilizing a large sample 
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size of participants with and without diabetes controlling for T2DM. The definition 
of cataracts should include all levels of lens opacity to ensure an outcome condition 
of adequate frequency.  A study with a wide age span would provide information on 
the age of onset of AR cataract valuable for monitoring future therapeutical 
treatment effects. Logistic regression analysis with the aforementioned criteria is 
useful both in terms of risk analysis but also for modeling the prevalence of AR 
cataract across the entire human age range which is absent in the current literature.  
Since T2DM, and now the use of statins, are increasing in prevalence in Canada and 
around the world, epidemiological studies on their impact must be ongoing if health 
care planners are to access the most up to date information.  Patient education about 
associated risks with statin use may encourage dietary and other life style changes to 
avoid developing statin-requiring conditions such as CVD and DM. 
 14 
Chapter 2  
Waterloo Eye Study:  data abstraction and population 
representation 
This chapter is published as follows: 
Machan CM, Hrynchak PK, Irving EL. (2011). Waterloo Eye Study: data abstraction 
and population representation. Optometry and Vision Science 88 (5): 613-620. 
Reproduced with permission from the American Academy of Optometry.  
 
This article was written by Carolyn Machan with guidance, editing and suggestions 
given by Elizabeth Irving and Patricia Hrynchak. The concept for the database was 
formulated by Elizabeth Irving and the database content was determined by 
Elizabeth Irving, Patricia Hrynchak and Carolyn Machan. Data entry for the database 
was done by Carolyn Machan except for the double-entered data for inter-abstractor 
repeatability which was done by Patricia Hrynchak and Elizabeth Irving.  Analysis 
was done by Carolyn Machan with input from Elizabeth Irving. The data for Figure 
2-2 was provided by Patricia Hrynchak.  
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2.1 INTRODUCTION 
There is a wealth of data contained within patient records and as such these records 
are a relatively inexpensive and readily available source of information. For 
example, no patient participation is required beyond consent to access their files, and 
little is required in terms of equipment beyond an adequate vehicle for data entry. 
This makes large sample sizes feasible. The data retrieved provide a snapshot of the 
conditions within the study groups for the selected slice in time. Consequentially, 
cross-sectional studies based on file review are the foundation of quality assurance 
programs and the planning of future health care services.
1
 In addition, the prevalence 
findings in these studies aid differential diagnosis in the clinical setting. Large clinic 
and hospital chart reviews are available from various parts of the world but no 
comparable Canadian studies using optometric files are known. The Waterloo Eye 
Study (WatES) database was created for cross-sectional studies of refraction, 
binocular vision and disease within an optometric clinic population. 
There are limitations to this type of study design. For example, clinic populations are 
not necessarily representative of the general population,
1
 and there are inherent 
difficulties with using retrospective rather than prospective data. The intent for 
which the clinical information was originally collected is not the same as that of the 
subsequent study. File data are abstracted from the patient records via an 
intermediary clinician(s) who did not collect the initial information.
2,3
 As such, the 
potential for abstraction errors and reviewer interpretation/bias exists. Finally, as 
Zadnik et al
4
 point out, there is also potential for missing data in file reviews. 
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A review of the literature offers several guidelines for ensuring data quality in file 
review studies. Research groups
2,3 
 point to the benefit of a trial launch of the 
abstraction tool within a pilot study. Review of a sample of files allows clarification 
of inclusion criteria and reassurance that all category options are mutually 
exclusive.
2,3
 Cassidy et al
5
 recommend carefully defining the data elements to be 
collected and monitoring data quality through reliability testing. The latter can be 
achieved through inter-abstractor repeatability measures. The Cohen’s kappa statistic 
is often employed for categorical data as it corrects for chance agreement, unlike 
percentage agreement rates.
6
 Numerical data lend themselves to intra-class 
correlation coefficient analysis as a reliability index.
7
 
The purpose of this study is to determine the quality of the WatES database, 
generated from a large scale file review of optometric patient charts with regard to 
data abstraction, missing data and representation of the population at large in terms 
of age and sex distribution. 
 
2.2 METHODS 
The WatES database was created from a retrospective review of 6,397 clinical files 
from the University of Waterloo, School of Optometry Clinic. Virtually all clinical 
testing at the School of Optometry Clinic is done by optometry interns in either their 
third or fourth year of study. These interns are supervised by registered optometrists 
who are ultimately responsible for all information within the record. The files 
reviewed represented patients of all ages seen over a one year period (January 2007 
to January 2008) from the Primary Care and Pediatric Service areas exclusively. 
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Special needs patients (defined as those having insufficient intellectual, visual or 
communicative capabilities or patient co-operation issues for their age, so as to limit 
testing or require adaptive testing) were not included. In cases where patients were 
seen more than once in the given time frame, the record that contained the most 
current data was used. The study was approved by the Office of Research Ethics at 
the University of Waterloo. The clinic has a procedure whereby implied consent is in 
place for all patients to have information from their clinic record reviewed for 
research purposes. Patients may withdraw their consent and files of persons having 
done so would not have been reviewed. 
An experienced optometric practitioner who was familiar with the clinic files 
abstracted the data, over a period of one and a half years. Before file review began, a 
specific list of data to be abstracted was determined. In compiling the list, 
consideration was given to the information normally gathered in a full eye 
examination at the clinic and thus generally available. A pilot test of the database 
template was done on 62 files (approximately 1%) for refinement of the list.  
The Primary Care and Pediatric service areas each have a standardized form for 
recording vision assessment results. For patient history, there is space provided for 
patient-specific information as well as checklist word prompts for routine vision and 
medical questions (see Table 2-1). The rest of the clinic record is divided into 
sections for recording visual acuities, binocular vision test results, refractive testing, 
ocular health evaluation, and a final section for recording diagnoses or ocular 
problems and recommended management.  
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Table 2-1: Case history word prompts on the University of Waterloo, 
School of Optometry examination records for the pediatric and primary 
care services. 
Date of visual assessment 
Reason for visit   
Developmental delays*   
School concerns*   
Pertinent birth history*   
 Pediatric & Primary Care Primary Care Only 
Visual symptoms  
 Flashes / floaters 
Blur Halos in vision  
Diplopia Asthenopia 
 Ocular itch or pain 
Ocular history 
History of eye surgery  
Presence of strabismus History of eye infection  
Use of spectacles History of eye injury 
Use of contact lenses  
Medical history 
 Hypertension 
 Heart disease 




Serious health concerns* Smoking currently 
 Diabetes 
 Headaches 
* Pediatric service only 
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Table 2-2: Clinical data collected in file review for Waterloo Eye Study 
database. 
1. Patient date of birth (day/month/year) 
2. Assessment date (day/month/year) 
3. Patient sex (M or F) 
4 Chief complaint and/or motivation for having an assessment 
5. Additional ocular or visual symptoms elicited in the case history 
6. Lens extraction(s) date(s) if applicable (year) 
7. Systemic disease diagnoses 
8. Current medications 
9. Entering prescription and final prescription (sphere, cylinder, axis, addition, 
and prismatic correction for right and left eyes) 
10. Refractive error 
11. Binocular vision data 
12. Best corrected monocular distance and near visual acuities 
 
The data elements were abstracted directly from the files into an Excel spreadsheet to 
create the WatES database. Ocular and systemic health were each given a cell for 
listing diagnoses. Twenty ocular and nineteen systemic diagnoses were screened in 
the files. There were a total of 80 variables abstracted in the entire database. The 
presence of disease only, rather than the severity or grade was abstracted in an 
attempt to exclude potential judgment variability between clinical practitioners and 
to avoid inconsistency in classification standards. The types of data reviewed are 
listed in Table 2-2. All variables were categorical except for age and refractive 
components, which were continuous data. Patient age was calculated from the 
difference between the examination date and the date of birth. This was done with a 
preprogrammed formula to avoid computation error. Race is not identified in the 
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clinic files, and therefore could not be included in the database. Refractive error was 
taken from subjective refraction testing results (sphere and cylinder in 0.25 dioptre 
units). Usually, a balancing technique is used in pre-presbyopes to achieve equal 
accommodation between eyes during refractive testing. If this had been done, then 
these results were abstracted, otherwise, the refractive results achieved through 
monocular testing were used. Retinoscopy results were entered into the database in 
cases where the file indicated the subjective refraction could not be done (e.g., very 
young children). The method of refraction was included, as well as the amount, test 
distance and method used to determine the near addition when applicable. The use of 
a cycloplegic agent was noted. Abstracted visual acuities were rounded to the nearest 
full optotype size (metric Snellen for distance and M notation for near). Binocular 
vision data included the presence (yes or no), direction (hypertropia, extotropia, or 
esotropia), test distance (6m or 0.4m), and frequency (constant versus intermittent) 
of strabismus. Near phoria measurements were categorized as being within (0–6 
exophoria) or outside (esophoria or greater than 6 exophoria) Morgan’s “normal” 
values, and entered as either 1,2 or 3 designations respectively. Accommodative 
amplitudes in pre-presbyopes as measured in dioptres by the push-up method were 
recorded. Vertical Maddox rod findings at near were recorded as ≤ 1 or >1 prism 
dioptres and any Broad H ocular motility restrictions were recorded as present or 
absent. All numbers abstracted were entered into the database with a precision 
clinically appropriate for the type of data. 
From the data, age and sex distributions for the clinic population were determined. 
Patients were binned in five year intervals to allow easier comparison to Statistics 
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Canada data reports which employ these age groups. However, as there were 
significantly fewer subjects over 84 years of age in WatES, all individuals ≥ 85 years 
of age were combined into one group. These age and sex distributions were 
compared to national population statistics for the closest available time period.
8 
 
Once abstraction of the clinic files was completed, re-abstraction of fifty (0.8%) 
randomly selected files was done by the original practitioner to look at intra-
abstractor repeatability. In addition, four hundred and twenty five of the original 
clinic files (6.6%) were randomly selected and independently abstracted by two other 
experienced practitioners to determine inter-abstractor repeatability. Cohen’s kappa 
statistic was used to examine agreement for the following categorical data: sex, near 
phoria grouping, chief complaint, systemic disease, ocular disease, and medication. 
Dichotomous grouping was used for all variables except near phoria which had three 
categories. Chief complaint was sorted into either presenting for the purpose of a 
routine eye examination (ree) only or presenting with symptoms as well. For the 
disease categories, samples of diagnoses were picked from the inclusion list based on 
anticipated cross-sectional analysis. The database cells were sorted and then screened 
for each of the diagnoses. A match was the inclusion or exclusion of the diagnoses in 
both entries for each file. For the “smoker” variable, patients were coded as current 
or not current smokers at the time of the assessment. To assess repeatability of 
medication data abstracted, a match required inclusion of all medications listed in 
both entries. Frequency of occurrence was determined since some categorical data, 
do not occur frequently, and this can have significant impact on kappa statistic 
repeatability measures. Higher kappa values are hard to achieve if the distribution of 
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the factor is extreme. Although there are no universally accepted benchmarks for 
interpreting the magnitude of kappa, the standards often referred to in the literature 
are those proposed by Landis and Koch in 1977.
9
 The following values for the kappa 
values were used: 0=no agreement; 0–0.2=slight agreement; 0.21–0.4=fair 
agreement; 0.41–0.6=moderate agreement; 0.61–0.80=substantial (or good) 
agreement; 0.81–0.99=almost perfect (or very good); and 1.00=perfect agreement. 
For continuous numerical data, repeatability was evaluated using the intra-class 
correlation coefficient.  
Missing information in the original patient file could be the result of illegible hand 
writing, failure to record clinical findings, inability to perform the test on the patient, 
or unavailable information at the time of the visual assessment (e.g., patient could 
not recall the name of their medication). Missing information rates were determined 
for clinic file information or measurements that would be expected to be available in 
all files. These included patient age and sex, chief or presenting complaint, screening 
for strabismus, near phoria measurements, refraction, and best corrected visual 
acuity. Information for other categories including ocular health, systemic diagnoses, 
medications, use of cycloplegic agent or prismatic correction, should have been 
recorded in the file when applicable, and a blank clinic file entry in these cases was 
taken to indicate an absence of the diagnoses, no use of medications or cycloplegic 
agent or no prismatic correction as opposed to missing data. However, it is not 
possible to verify these assumptions and classification of missing data in these 




WatES patient ages ranged from 0.2 to 93.9 years. The mean and median ages of this 
clinical population were 42.5 and 45.1 years respectively. With the exception of the 
oldest group, all age groups are reasonably represented with between 3.6 and 7.4% 
of the study population. Age distribution rates were relatively stable averaging 
approximately 6.6% through childhood to age 24 years. The rate decreased after 24 
years of age and was lowest between 25 and 40 years (3.8% average). The rate rose 
again after 39 years to 5.3% and remained around 6.4% between 50 and 80 years of 
age. This was followed by a rapid decline in patient numbers after 79 years of age 
(2.8% average). Figure 2-1 shows the study distribution relative to federal census 
statistics. It can be seen that the WatES database over-represents individuals less 
than 10 years of age and over 65 years of age relative to the general population and it 
under-represents the population between 10 and 20 and 25 to 50 years of age. When 
compared to a cross-sectional study with a stratified random sampling of 133 
Canadian optometric practices
10
 the age distributions were generally similar in the 
two studies. However, the WatES database had 14.50% of its population 9 years of 
age or under compared to 8.58% in the Robinson
10
 study. Conversely there were 
more 35–54 year olds in the Robinson data
10




Figure 2-1.  Comparison of Waterloo Eye Study patients to national 




There were 3458 female patients representing 54.1% of the clinic population and 
2939 male patients, or 45.9%. The mean age of WatES females was 42.6 years and 
42.3 years for males. The median ages were 45.1 and 45.5 years for female and male 
patients respectively. Although there were 8.2% more females than males in the 
clinic population, the overall distribution profile was similar between sexes. The 
exceptions were a slightly greater number of male pediatric patients than female, and 
a greater number of females creating a peak at ages 20–25 years. In comparison, 
Canada reportedly had 51.0% females compared to 49.0% males.
8 
Repeatability of file data abstraction, determined from double-entry analysis of the 
same abstractor (intra-abstractor) and different observers (inter-abstractor) are 
summarized in Tables 2-3 and 2-4. For categorical data, the kappa (K) values were 
above 0.80 (very good agreement) for all but 5 inter-abstractor categories (Table 2-
3). Of these 3 were above 0.60 (good agreement). The migraine and smoking 
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categories had low frequency of occurrence values and agreement rates of 0.41 and 
0.26 respectively. Intra-abstractor kappa values were generally high with all but two 
values above 0.80 and both of those above 0.74 (Table 2-3). Intra-class correlation 
co-efficients for continuous data were very high for both intra- (>0.95; Table 2-4) 
and inter-abstractor (>0.90; Table 2-4) comparisons. One notable exception was best 
corrected distance acuity of the left eye (0.83; Table 2-4). Although noticeably lower 
than the rest, it is still quite high. 
 
Table 2-3.  Intra-abstractor (N=50 files) and inter-abstractor (N=425 files) 
repeatability for nominal data from double entered files: frequency of 
occurrence (% of N files double entered), disagreement rate (%), and kappa 
(K) value (95% CI–truncated at 0 and 1.00). 
 Intra-abstractor Inter-abstractor 
Categorical 
Data Type 



















































































































Medication 75%, 10% K=0.78 (0.60–0.96) 52.2%,8.2% K=0.84 (0.78–0.89) 
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Table 2-4. Intra-abstractor (50 files) and inter-abstractor (425 files) 
repeatability for continuous data from double entered files: Disagreement 
rates (%) and correlation coefficient (ICC) (95% CI). 
Quantitative Data Type Intra-abstractor Inter-abstractor 
Age 4%, ICC=1.00 6%, ICC=1.00 
Refraction–right sphere 4%, ICC=1.00 3% ICC=1.00 
Refraction–right cylinder 2%, ICC=1.00 2% ICC=1.00 
Refraction–left sphere 4%, ICC=1.00 
5%, ICC=0.99 
(0.99-0.99) 




















Missing data rates are summarized in Table 2-5. Our review of the WatES database 
yielded low rates (<1%) for most of the applicable variables. There were only 3 files 
without the sex recorded and only 14 with no chief complaint recorded (including 
presenting for a routine eye examination). There were 11 patients who were 
monocular or used eccentric viewing and therefore screening for the presence of 
strabismus would not have been appropriate. Of the remaining 6386 file entries, 
there were 44 that did not have distance and near strabismus screening results in their 
files (<1.0% missing data rate). There were 6165 file entries of the 6386 that did not 
have strabismus at near for which near phoria testing was appropriate. However, 457 
did not have near phoria testing results (7.4% missing data rate). The majority of 
these were younger patients, for whom accurate fixation required for alternating 
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cover test would be difficult and/or the child may not have understood the 
instructions for the test.  Refractive testing results were available for both eyes in 
close to 98.8% of the patient files. Best corrected distance visual acuity 
measurements were available for at least one eye per patient in all but 31 files.  
 
Table 2-5. Percentage of missing data elements from the 6397 records in 





Files with missing data 
(%) 
Age 0 0 
Sex 3 <1 
Chief complaint 14 <1 
Presence of strabismus* 44* <1 
Near phoria** 457** 7.4 
Refraction 75 1.2% 
Best corrected visual acuity 31 <1 
* 44 of 6386 patients who do not have eccentric viewing or monocular vision 
** 457 of 6165 patients without near strabismus 
 
2.4 DISCUSSION 
The strength of the WatES database lies in its sample size and an age range that 
spans from infancy to the geriatric years. A full year of clinic visits should approach 
the cross-section of patients generally seen in the clinic. Based on the analysis 
performed here, this database should provide valuable information about the 
prevalence of and associations between many ocular conditions within this 
population.  
The median age of the WatES population was higher than the median age for 
residents in Canada, which has been estimated at 39.5 years.
8
 Overall, the clinic 
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population under-represents 25 to 50 year olds, and over-represents children and 
seniors compared to the general population. Steady clinic visit rates in childhood 
may point to public awareness and education on the importance of early vision 
screening. The decreased rate of ocular assessments after 25 years of age until 39 
years of age is likely attributable to the relative stability of refraction and ocular 
health during that time. The rise after 39 years of age coincides with the onset of 
presbyopia. The fact that in 2007, provincial health insurance (OHIP) only covered 
eye exams for all residents under the age of 20 and over the age of 64 could 
influence examination frequency for certain age groups. However, records of earlier 
clinic visits when OHIP insured all age groups show similar trends with regard to 
age distribution to that of the WatES population (Figure 2-2). 
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Figure 2-2.  Comparison of the age distributions of patients seen at the 
the University of Waterloo School of Optometry Primary Care Clinic 
from 1990 to 2007 including the Waterloo Eye Study. (Data prior to 2007 
were obtain from Primary Care Clinic billing records by P. Hrynchak 
and patients seen in the Pediatric Service have been removed from the 
WatES data for the purpose of this comparison.) 
 
The WatES age distribution is fairly similar to nationally representative optometric 
practice with the exception of the youngest ages. This is presumably because the 
University of Waterloo, School of Optometry clinic has a dedicated clinic for 
pediatric vision assessments. The high level of ocular assessments at ages 20–25 
(Figure 2-1), may be representative of frequent refractive changes and increased use 
of contact lenses in those age groups. However, the City of Waterloo population is 
higher than the national and provincial averages for this age group and this may also 
be a contributing factor.
8
 The age distribution for the national population is not 
skewed downwards in early adulthood, but instead remains evenly distributed from 
the teen years into the middle ages. There is a steady decline in age distribution of 
Canadians older than 59. The result is lower median ages for the general population 
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compared to the clinic group. In 2004, the Canadian Centre for Health Information 
conducted a survey on behalf of Statistics Canada to determine the prevalence of 
vision problems among Canadian seniors. Their report, the Canadian Community 
Health Survey (CCHS) found 82% of seniors (ages 65 and over) had some form of 
vision problem in 2003.
11
 This included any functional visual concerns experienced 
such as reading difficulties, inability to see the television and being visually excluded 
from driving a car. However, 78% were correctable through proper management.
11
 
This along with increasing risk of ocular disease could explain the higher percentage 
of the 65 to 84 year old WatES patients seeking eye exams than other age groups in 
the national population. The oldest group (over 84) comprised approximately 2% of 




Overall there were more females than males in the clinic population with a peak at 
ages 20–24 years. The sex difference in the peak may in part result from the fact that 
optometry students are predominately female (70%) and optometry students are 
strongly encouraged to have an eye examination in the clinic at the outset of their 
training. In comparison the national population more closely approached 50% for 
each sex. The Robinson study
10
 also had a somewhat skewed sex distribution of 
57.2% females and 42.8% males. Possible reasons for a higher percentage of females 
in optometric populations than the general population include females seeking 
routine optometric care in general and/or more females having visual concerns than 
males. The aforementioned CCHS results indicate that there were a higher 




of those experiencing vision problems, there was no difference in consultation rates 
between men and women. A consultation was an office visit to either an optometrist 
or ophthalmologist in the past year.
11
  
The quality of the database depends on the consistency in the abstraction methods 
used and how the file information was interpreted by the reviewer. The abstractor for 
this study had used the files for many years. While the abstraction process was aided 
by this familiarity, there was a potential for assumption that needed to be avoided. 
The fact that the data were entered manually over an eighteen month period does not 
appear to be a major factor as the intra-abstractor analysis shows very high 
agreement. Since the double-entered files were re-entered after the initial data 





 data are only considered reliable if similar results would 
be obtained if other experienced and/or trained observers had entered it. Allison et 
al
3
 looked at techniques to improve data quality during chart review. Their literature 
review revealed higher disagreement rates when abstractors were required to use any 
clinical judgment or analysis during file reviews. Likewise, Yawn et al
13
 studied 
inter-rater reliability and found that free-text rather than numeric variables was very 
challenging for abstractors. Thus, one could expect categorical data that required 
some interpretation (e.g., ocular disease) to be less repeatable than data that did not 
(e.g., sex) or continuous data that involved simply copying numerical results (e.g., 
refraction data). For our database, disease diagnoses required searching the record’s 
case history, clinical findings and the diagnostic summary at the end, whereas, the 
numerical data were generally found in designated areas of the file. Numerical data 
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generally require less interpretation, but are more prone to accidental transposition 
when entering. Intraclass correlation coefficient (ICC) values were all high for the 
continuous data. This suggests that even when values were not agreeing exactly, they 
are not significantly different. The Cohen’s kappa statistic values suggest very good 
agreement for most categories but span a range from “fair” to “perfect”.  Most of the 
categorical variables selected were dichotomous, and higher Kappa values can be 
found when using only two coding classifications compared to many.  Kappa 
coefficient values do not indicate why there is a lack of agreement and in the case of 
low kappa values, this must be determined though data examination. Systematic 
differences in the case of inter-abstractor file review are often the result of ambiguity 
in the definition of a diagnosis not clarified ahead of time.
6
 Zadnik et al
4
 looked at 
the inter-clinician agreement for two observers when data were abstracted 
retrospectively from patients’ optometric charts. They found good repeatability 
between the two trained but inexperienced collectors reviewing 100 patient records 
over five visits. Their results suggested that a large retrospective database of at least 
1000 patients would benefit from double entry of demographic information (e.g., 
gender or age) in 2% of the files. Our double-entry file numbers exceed that 
recommendation. Statistically, the minimum calculated sample size required for data 
abstraction repeatability measures for this study is 276 files.
14
 With 425 double 
entries we also exceed this. 
Rozewski
12
 found agreement rates between 70 and 75% or more for the majority of 
categorical data. Zadnik et al
4
 found disagreement rates for demographic variables 
(e.g., sex or age) were relatively small (between 0 and 12%). For clinical ocular data 
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(e.g., case history specifics or ocular disease) disagreements rates were still 
reasonable but somewhat larger (3 to 26%)
4
. In 2008, looking at intra-rater 
agreement for 10 abstractors, six data categories and 110 randomly selected files out 
of 1,433, the Asthma Care Program in Ontario, found an overall kappa of 0.81 for 
intra-rater abstraction and an inter-rater agreement of 88% and inter-rater kappa 
statistic of 0.75.
15
 Our results have the same or better agreement rates than previous 
studies, since agreement rates were 83% or greater for all information analyzed and 
the mean intra-rater and inter-rater kappa statistics were 0.90 and 0.82 respectively. 
Similar to previous studies, agreement rates were higher for categorical demographic 
variables than for categorical clinical data and repeatability was high for numerical 
clinical data.  
 
2.5 CONCLUSIONS 
It is possible with retrospective clinic file review for both qualitative and quantitative 
data to be reliably abstracted providing a wealth of pertinent information for 
studying health care needs. However, care must be taken to consider how the data 
were initially recorded, specifically what is to be abstracted, and how it should be 
entered. As healthcare records move from written to electronic files, the ease of 
abstraction, rate of abstraction and reliability of the abstracted data should improve, 
which is encouraging for the undertaking of any similar studies in the future. The 
WatES includes patients across the entire age spectrum providing a reasonable 
distribution of all age groups. The sex distribution is skewed somewhat towards 
females compared to the general population, but again there is fair representation of 
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both males and females. The sample size and good inter-abstractor repeatability of 
this database provides the statistical power and quality necessary for subsequent 
cross-sectional observation and analytical studies of prevalence and associations. 
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Chapter 3 
Modeling the prevalence of age-related cataract: Waterloo Eye 
Study 
 
This chapter is published as follows: 
Machan CM, Hrynchak PK, Irving EL. (2011). Modeling the prevalence of age-
related cataract: Waterloo Eye Study. Optometry and Vision Science 89 (2)              
(e-published ahead of print -doi: 10.1097/OPX.0PX.0b013e31823ee062). 
Reproduced with permission from the American Academy of Optometry. 
 
This article was written by Carolyn Machan. Guidance, editing and suggestions were 





Cataract is any opacity of the natural crystalline lens that degrades the optical 
quality.
1,2 
The World Health Organization (WHO) identifies cataract as the cause of 
approximately 50% of the world’s blindness; blindness being defined as best 
corrected visual acuity of less than 3/60 or a visual field loss to less than 10 
degrees.
3-5
 This number drops to 5% in North America, primarily due to accessibility 
of cataract extraction surgery and its restoration of visual function.
3
 Unfortunately, 




Only age-related cataracts contribute significantly to these public health concerns, as 
congenital and other types are rare in comparison.
7
 Age-related (AR) lens changes 
are typically described as three distinct morphological entities: nuclear sclerosis 
(NS), cortical cataracts (CC) and posterior sub-capsular cataracts (PSC) 
2,5,7
 For 
those who cannot access surgery, the resultant visual disability from AR cataract can 
result in job loss and increased financial strife.
5
 In many places, it is women who 
suffer these fates as they are particularly susceptible to surgical care barriers.
3,5,8
    
With increasing life expectancy worldwide, the overall burden of AR cataract is 
expected to climb. Identifying the onset and prevalence of any AR lens opacity is 
important as non-surgical treatments and preventative measures are investigated. It 
has been suggested that delaying the onset of cataracts could have significant 
financial consequences for public health. For example, by delaying the onset by ten 
years, it has estimated that there would be a 45% reduction in cataract extraction 
rates and a 50 % decrease in the prevalence of cataract in USA.
5,7,9
 Similar results 
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could be expected in Ontario, Canada where there has been a significant increase in 
lens extractions rates.
10
 Hatch et al
11
 found that the number of extractions in Ontario 
more than doubled between 1994 and 2005 in patients over 65. While cataract 
prevalence studies exist outside of Canada, Canadian data are limited. Robinson
12
 
used a large scale cross-sectional clinical study to look at eye disease prevalence in 
representative optometric practices across Canada between mid-October 2000 and 
the end of January 2001. Based on reports from optometrists, she found an overall 
cataract prevalence of 12.85% +/- 0.42 (CI 95%) in a study population of 24,570 
patients (ages 9 to 85 years). However, the authors are unaware of Canadian data 
on the frequency of each AR lens opacity type separately and of differences in 
prevalence between males and females.  
The paper has several objectives. The first is to provide Canadian clinical optometric 
data on AR, NS, CC and PSC cataract prevalence to assist in public health planning. 
Comparison of these results to optometric populations elsewhere may reflect 
differences in our health care delivery. The second objective is to offer additional 
information on sex difference as results have varied somewhat in previous studies 
warranting further investigation. Thirdly, to model age related prevalence over the 
entire lifespan through logistic regression analysis to demonstrate the onset of AR 
cataract which is not found in the current literature. Finally, when preparing for this 
investigation, the literature review revealed inherent difficulties in comparing 
previous cataract studies in terms of different definitions of cataracts and age groups 
involved. Thus, this manuscript will highlight those difficulties and offer methods to 




The Waterloo Eye Study database (WatES) was developed from a retrospective 
review of 6397 clinical records from the University of Waterloo, School of 
Optometry. The collection methods, abstraction repeatability rates and patient 
distribution profile have been detailed in an earlier report.
13
 Various types of visual 
and ocular variables were abstracted on patients (ages 0 to 93 years) seen over a one 
year period (January 2007- January 2008) in the Primary Care and Pediatric services. 
Ocular disease data collected included the presence and type of any clinically 
apparent cataract, and any history of aphakia or pseudophakia. For patients that had 
had cataract extraction in either one or both eyes, surgical dates (year) were 
recorded. For the WatES database, clinically apparent cataract was defined as a 
recording of grade one or greater NS, and any PSC, CC, anterior sub-capsular, 
traumatic, inflammatory, metabolic or congenital cataract. For this investigation, NS, 
CC, and PSC or their associated lens extraction (LE) were considered AR cataract 
regardless of patient age. In 2007, crystalline lens evaluation was part of the routine 
ocular assessment at the University of Waterloo, School of Optometry. Pupil dilation 
with 1% tropicamide was the routine practice for adult patients. In younger patients, 
mydriatic drops were used when non-dilated pupil size did not allow sufficient 
evaluation of posterior segment ocular health. Crystalline lenses were examined by 
biomicroscopy using direct and retro-illumination. Lens opacity type and subjective 
severity grade were recorded with text in a designated area on the clinic record. A 




Typically the word ‘clear’ or a designated grade and type of cataract were written. 
Blank textual references to the crystalline lens existed in less than 1% of the files and 
were taken to mean an absence of cataract. Rarely, only the words “trace” or “slight” 
in association with nuclear sclerosis were given and were interpreted as less than 
grade 1 and not included as a diagnosis. A report of lens opacity in either eye was 
accepted as a diagnosis for this investigation. Patient age was electronically 
calculated in the spreadsheet from the date of assessment and the patient’s birthday, 
and this information was available for all database files. 
The overall prevalence (%) of any AR cataract was determined for this optometric 
clinic population and for male and female subgroups. All WatES patients were then 
sorted by age (years) into those without AR cataracts and into the following AR 
categories: 1) patients with any AR cataract but no LE, 2) patients with unilateral LE 
and AR cataract in the other eye, and 3) patients who had bilateral LE due to AR 
cataract. The percentage of the sample size by age was calculated for each category. 
As there were few subjects over eighty-eight years of age, those subjects were 
combined into one age group (>88years). Logistic regression analysis was done to 
determine a prevalence probability function for the total of the three AR cataract 
groups. From this function, the age for 50% prevalence was estimated. A similar 
analysis was then done to compare male and female subgroups. 
Further investigation looked at the prevalence (%) of each AR cataract type (NS, CC, 
PSC or applicable LE) independent of whether they were mixed presentation. 
Patients that had undergone unilateral LE were categorized by the type of lens 
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opacities in the other eye. After age adjusting, sex differences were reviewed for 
statistical significance for each cataract category through logistic regression analysis. 
Next, patients with AR cataract were sorted by the following categories for males 
and females: NS only, CC only, PSC only, mixed cataract (any combination of the 
three), and bilateral LE. Again, patients that had undergone monocular LE were 
categorized by the type of lens opacities in the other eye. The percentages of male 
and female AR cataract patients were determined for each category and distribution 
differences between men and women were obtained. Finally, the age at first lens 
extraction was calculated for applicable patients from patient age and reported 
surgical dates. The mean age at initial cataract surgery was determined and compared 
for the male and female subgroups. 
 
3.3 RESULTS 
Repeatability rates for entering WatES variables in the database were determined and 
found to be high.
13
 Cohen Kappa was calculated for the following categorical data: 
NS, 0.88; CC, 0.80; PSC, 0.85; LE, 0.92 and patient sex, 0.96. Intra-class correlation 
coefficient, used for continuous data, was 0.95 for patient age. 
Males (n=2939) accounted for 45.9% of the population with a mean age of 42.3 
years, and females (n= 3458) comprised 54.1% of the population with a mean age of 





Clinically apparent cataract was identified in 2332 patients (36.5% of this optometric 
population). Of those, only 75 patients (or 1.2%) had lens opacities attributed to 
etiologies other than age and were included in the group without age-related 
cataracts. Thus, 2257, or 35.3% of the study population, had AR crystalline lens 
changes or had prior LE for NS, CC or PSC. The prevalence was somewhat higher 
for males (n=1058 or 36.0%) than females (n= 1199 or 34.7%) but the difference 
was not statistically significant once age matched. Looking strictly at the occurrence 
of AR cataract at the time of assessment, and excluding those with bilateral LE, the 
prevalence of WatES patients with existing AR changes was 1940 out of the 6397 
patients, or 30.3%. In this case, the sex difference in prevalence shows a slight 
increase with males at 31.7% and females at 28.4%, suggesting more female patients 
had undergone bilateral LE than males. 
Fig. 3-1 illustrates the age distribution of WatES patients grouped by year with no 
AR cataract and the three AR subgroups. The rate of bilateral lens extraction 
progressed steadily from 70 years of age onward. The logistic regression line is 
shown for the prevalence of AR cataracts as a function of age. The prevalence 
increased in a sigmoid manner after age thirty-eight approaching 100% by 75 years. 
From this function, 50% prevalence can be estimated at age 56.6 years (56.3- 56.9, 




Figure 3-1. The prevalence of age-related (AR) cataract as a function of age 
in all Waterloo Eye Study (WatES) patients. The predicted prevalence 
from logistic regression analysis is shown.  
 
Examining each type of age-related cataract individually, 28.8% of all WatES 
patients had NS, 9.9% had CC, 3.6% had PSC and 14.0% had bilateral LE. Nuclear 
sclerosis occurred progressively after age 38 for both male and female WatES 
patients and there was no significant sex difference in its prevalence. Fifty percent 
prevalence NS is estimated at 57.9 years of age in the WatES population. Being 
female in this population was associated with an increased prevalence of cortical 
cataract (Odds Ratio; OR= 1.54, 95% CI 1.27 to 1.88). This association was even 
greater for females over 59 year of age (OR=1.66, 95% CI 1.35 to2.05). Fig. 3-2 A) 
shows the predicted prevalence of CC in female and male WatES patients as a 
function of age using regression analysis. From this, the age of 50% prevalence for 
CC can be estimated at 76.7 years of age for females compared to 82.6 years of age 
for males. In general, CC prevalence increased at a later age than NS, only rising 
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appreciably after age 50 compared to 38 for NS. Posterior subcapsular cataract was 
the least prevalent type of cataract. Males had a higher prevalence of PSC than 
females in this population, but this difference fell slightly short of statistical 
significance, in part due to the low frequency of this opacity. Ten percent prevalence 
of PSC, determined by regression analysis, was estimated at 69.7 years of age for 
males and 72.1 years of age for females. Fig. 3-2 B) shows the predicted prevalence 
of bilateral lens extraction for both subgroups. Although males in this population 
appear to have a slightly greater rate of bilateral LE than females before 67 years of 
age, females past this age have an increasingly higher rate of LE than men. A 50% 
predicted prevalence of bilateral LE is reached at 84.6 years for females and at 90.5 
years for males. The odds of having bilateral lens extraction in females was 1.41 
(95% CI, 1.09–1.84) times that of males. The mean age of first cataract extraction in 
this population was 72.0 years +/- 10.3 (SD) of age. Females had a significantly 




Figure 3-2. The predicted prevalence (%) of cortical cataract (A) and 
bilateral lens extraction (B) in female (light grey) and male (dark grey) 




Fig. 3-3 shows the distribution of AR cataract for male and female subgroups when 
separated into mixed and homogenous types. Female patients with AR cataracts had 
a higher rate of bilateral LE (15.9% versus 11.9%) and a higher rate of mixed 
cataract (31.6% versus 29.3%) than males. Consequentially, there were more male 
cataract patients with NS only (55.1%) than females (48.2%). Due to the 
considerable predominance of NS in patients with AR cataracts, over 99% of mixed 
cataracts had NS as one of the components for both sexes. Whereas, CC occurred in 
87.1% of mixed cataracts in females, it attributed to only 76.5% in males. 
Conversely, PSC was reported for 35.2% of mixed cataracts in males and only 
25.9% in females. 
 
Figure 3-3. The distribution of mixed and homogeneous cataract types in 
male and female Waterloo Eye Study (WatES) patients with age related 




Although retrospective file reviews can be useful in determining associations 
between factors and suggesting potential disease etiologies,
15
 they are not without 
limitations. They cannot demonstrate causation since the temporal precedence of the 
cause occurring before the effect cannot be ascertained in studies that measures both 
factors at the same time. Additionally, confounding variables may not be equally 
distributed within the groups when doing risk analysis. As discussed in the methods 
paper for the WatES database (see Machan et al 2011
13
) data from clinic populations 
are not necessarily representative of the general population and prevalence or 
demographic data from clinic populations must be viewed in light of the population 
from which they were obtained. Finally, the intent for collecting the file information 
originally is not the same as that of the subsequent study.  
In all cataract studies, disease definition is important. First, lens opacity progresses 
continuously with age and a threshold of sufficient optical degradation to be called 
“cataract” for each opacity type must be decided.
16 
Second, the detection and grading 
of lens opacity requires clinical judgment. Several large studies employed well 
recognized grading systems, such as the LOC III or the Wisconsin Cataract Grading 
System
16-18
 that use coloured photographs to match density, colour, and/or area 
covered by lens opacities. Unfortunately many investigators have chosen different 
grading points on these scales, especially for nuclear sclerosis, making comparison 
between studies difficult.
5
 Demonstrating standardization between examiners in 
retrospective file review is even more difficult. However, unlike the fore-mentioned 
studies, we were interested in the onset of clinically apparent cataract rather than 
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when cataracts become visually significant. There should be greater inter-clinician 
agreement in whether lens opacity is seen or not seen (grade one at least), than in 
determining the actual severity of the opacity. Within the clinic files, failure to detect 
opacities may result from incomplete or declined dilation on the part of the patient. 
As a result, analysis of the collected data is more likely to yield a conservative 
estimate of the prevalence of age-related lens opacities in this clinic population. The 
term “cataract” is often reserved for opacities associated with vision loss and earlier 
studies included acuity determinants of visual significance as an indicator of cataract 
progression.
1,5,19
 This was not required based on our goal to include any clinically 
apparent lens opacities and would become imprecise in the presence of any other eye 
disease. 
Previous studies have reported cataract prevalence for discreet age categories 
causing comparison difficulties of odds ratios with studies using different age 
groupings. Our study approach is unique in that it takes in the entire lifespan. 
Through logistic regression analysis a prevalence functions can be generated, 
allowing prevalence estimates and odds ratio values for any age group, facilitating 
study comparison. We can also determine age estimates for any specified prevalence 
levels. Furthermore, since we include all levels of lens opacity, we can determine the 
age of onset for AR cataract. 
One could expect the prevalence of cataract to be somewhat higher in a clinic 
population than the general population, as patients with previously detected cataracts 
have been encouraged to maintain regular ocular health assessments to monitor 
progression of the lens opacity. Visual symptoms resulting from lens opacity may be 
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1
a motivation to seek an eye examination.
9
 This may explain the lower prevalence 
rates for age-related lens changes or extraction in the Framingham Eye Study cohort 
compared to our study.
19
 The Framingham Eye Study (1973–1975) was one of the 
earliest large scale American studies to report prevalence rates for cataract (defined 
as any early to later age-related lens changes or aphakia). The authors reported 
prevalence rates of 41.7% in persons 52–64 years of age rising to 91.1% in persons 
75–85 years.* Comparatively, prevalence values of 58.3% and 99.5% were found for 
the same age groups in our study. The Robinson Study had a much lower prevalence 
of cataract than in our study, but it is important to note that the decision of inclusion 
was left to the discretion of the reporting private practice optometrists in their 
study.
12
 A diagnosis of “cataract” in private practice may apply to more advanced 
lens opacity levels than in our study, which aimed to report from a threshold of early 
monitoring. The Beaver Dam Eye Study was done as an American population-based 
study with a cohort of 4926 patients examined initially between 1988 and 1990. At 
the baseline examination, their patients between ages 43 and 84 had a 16.3% 
prevalence of any CC, and a 6.0% prevalence of any PSC.
18
 When our data was 
similarly sorted, the prevalence of CC and PSC was again comparable at 18.1% and 
6.8% respectively.  
Interestingly, the Framingham Eye Study was done over 25 years ago before phaco-
emulsification technique for intra-ocular lenses became the standard for cataract 
                                           
* These numbers came from a recalculation of the original Framingham Eye Study data including all 
early to late lens changes regardless of visual acuity and ignoring the original calculation criterion of 
including only those with a reduced visual acuity of 6/9 or worse. (Sperduto RD, Seigel D. Senile lens 
and senile macular changes in a population-based sample. Am J. Ophthalmol 1980; 90:86-91.) 
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surgery. Erie et al
20
 used the Rochester Epidemiology Project databases to show 
when phaco-emulsification replaced extracapsular extraction methods, the rate of 
cataract surgery increased linearly over time in their study group. Only 72 of the 
2631 Framingham cohort being followed were designated as aphakes (2.7%) 
whereas 368 out of 2535 WatES patients between 52 and 85 (14.5%) had had 
cataract surgery in one or both eyes.
1
 
Some studies have shown an associated risk for NS with being female;
18,21,22
 others 
have not found this association.
16,17,23,24
 However, the sex difference for CC found in 
our study has been consistently shown in other investigations. The POLA study 
found an increased odds of cortical cataracts for females (OR= 1.67), as did the 
Visual Impairment Project (age-adjusted relative risk of 1.8; 95% CI, 1.3-2.6) and 
the Lens Opacities Case-Control Study (OR= 1.51).
16,23,24
 The Blue Mountains Eye 
Study looked at sex differences for ten-year person-specific incidences. After 
adjusting for age, women had a significantly higher incidence than men of cortical 
cataract (30.8% versus 24.4%, p=0.007).
21
 Hormones have been implicated in female 
cortical cataractogenesis
24-26
 but this has not yet been sufficiently substantiated. 
Literature review finds less evidence for sex differences in the prevalence of PSC.
8
 
The higher occurrence of CC in women and a slightly higher PSC prevalence in men 
may explain the observation that women in the WatES population have a greater 
overall prevalence of bilateral cataract extraction but a later mean age of first lens 
extraction. Initially, cortical cataracts are associated with a gradual decrease in vision 
until the opacity reaches the visual axis of the crystalline lens. Consequential lens 
extraction from this type of cataract comes at a more advanced stage of development 
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than posterior subcapsular cataract which rapidly causes visual impairment. This was 
reported in both the Blue Mountains Eye Study and the Beaver Dam Eye Study, 
which found that the presence of PSC was associated with the greatest rate of 
incident cataract surgery over NS or CC.
27,28
 There may be differences in the type of 
cortical change that occurs in women as well. The Framingham Eye Study noted that 
of the 2631 patients they screened, cortical vacuoles were slightly more prevalent 
than spokes among men while spokes were observed substantially more frequently 
than vacuoles in women’s lenses.
1
 
Our result that males had an earlier mean age of first lens extraction than females is 
comparable to other studies. In a retrospective review conducted from the operating 
records of 8256 cataract surgeries performed at the Waterford Regional Hospital, 
Republic of Ireland, O’Reilly et al found the mean age at surgery between 1986 and 
2003 to be 72.32 years +/- 12.21 (SD) years for males and 74.89 +/- 11.03 (SD) for 
females. The age profile did not change significantly over the 18 year study period; 
however there was a significant increase in the proportion of women having lens 
extraction.
29
 Bilinska et al, in a Polish study of surgical records between 1997 and 
2002, found that for their 4385 patients, women were operated on at a mean age of 
71.1 years whereas the mean age for men was 69.1 years. A statistically significant 
increase in these ages was occurring over time.
30
 The prospective POLA Study in 
France, found an increased risk of having had bilateral cataract surgery for the 
female sex (OR= 3.03).
16
 Comparatively, the Blue Mountains study (2008) found a 
mean age at cataract surgery to be 75.8 years with no significant sex difference. 
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Investigations on age-related cataracts will continue to be important. Crystalline lens 
changes are responsible for many visual concerns including refractive changes, 
decreasing acuity, loss of contrast sensitivity and glare concerns.
2
 In mature patients, 
a significant amount of their eye examination is dedicated to dealing with these 
issues. This along with overall increasing surgical costs for lens extraction will 
continue to drive the search for therapeutic or preventative measures for this 
prevalent disease.
16
 Interestingly, several studies have suggested that the presence of 
cataracts is a commanding predictor of mortality.
31,32
 Therefore the prevalence of 
cataract in a population may be a marker for the overall health of its members. 
3.5 CONCLUSIONS 
Our results confirmed the well known risk of age for cataract development in both 
males and females. Within this optometric clinical population, age-related cataract 
was a common finding in patients over fifty-six years of age with nuclear sclerosis 
being the predominant type of cataract. Being female was associated with an 
increased prevalence of cortical cataract, and consequently mixed cataracts, and an 
increased rate of surgical intervention. Despite this, females had a greater average 
age of first cataract extraction than males. The prevalence of cataract increased in a 
sigmoid progression as a function of age that could be modeled through logistic 
regression. This novel way of presenting prevalence data is recommended as an 
improved way to compare results between studies and for predicting prevalence at 
any age for the reported population. 
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Chapter 4 
Type 2 diabetes and statin use associated with age-related cataract: 
Waterloo Eye Study. 
 
This chapter is submitted as follows: 
Machan CM, Hrynchak PK, Irving EL. (2011). Type 2 diabetes and statin use 
associated with age- related cataract: Waterloo Eye Study. 
 
This article was written by Carolyn Machan. Guidance, editing and suggestions were 





Age-related cataracts have been identified as a prevalent ocular disease in patients 
over 39 years of age.
1–5
 The financial and functional burdens of this inevitable aging 
process are known, both in terms of surgical costs and visual impairment when 
surgery is inaccessible or pending.
6–10
 Accordingly, it is important to identify factors 
that accelerate cataract development and to minimize exposure to them through 
public health measures. Several large population studies have identified the diagnosis 
of diabetes mellitus (DM) as a risk factor for age-related (AR) cataracts.
11–17
 
However, which types of AR lens opacities are involved varies between studies, 
namely, whether it is nuclear sclerosis (NS), cortical cataract (CC) and/or posterior 
subcapsular (PSC) that is associated with DM. Health care planners are concerned 
that the prevalence of DM is rising at a pandemic rate, with over 300 million people 
predicted to be affected globally by the year 2025.
18
 The Canadian Diabetes 
Association
19
 (CDA) reports that the number of people diagnosed with DM in 
Canada grew by 70% between 1998 and 2005 and that more than 10% of Canadian 
healthcare costs are spent on dealing with DM and its complications. Type 2 diabetes 
mellitus (T2DM), predominantly insulin resistant with relative insulin deficiency, 
accounts for 90% of all cases of DM in North America.
18
 Contributing to the high 
number of people with DM are an aging population, people living longer with 
diabetes, increased immigration of high-risk populations, growth of high-risk 
aboriginal populations and rising obesity rates.
19
 Many people with T2DM have 
concurrent dyslipidemia and are at higher risk of cardiovascular disease and stroke. 
The results of several studies from around the globe have provided evidence that 
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taking statins (HMG-CoA reductase inhibitors) reduces cardiovascular risks in 
patients with DM.
20–22
 Consequently, statins are a class of pharmaceuticals 
commonly prescribed for patients with DM to lower cholesterol.  
Early clinical trials did not find significant lenticular changes with statin use of less 
than five years.
23–26
 However, a very large recent cohort study from the UK reported 
an association between statin use and increased risk of cataracts, suggesting that 
further study is warranted.
27
 Furthermore, the morphological types of AR cataract 
associated with statin use have not yet been investigated. 
The authors are unaware of any Canadian studies investigating the impact of DM on 
the prevalence of age-related cataract. In this study we compare the prevalence of all 
clinically apparent age-related lens opacities in non-diabetic (ND) and T2DM 
subgroups from a large clinic population at the University of Waterloo, School of 
Optometry. We also look for any age-matched differences in the subgroups for NS, 
CC, and PSC separately. The impact of these differences are investigated through 
distribution comparison of homogeneous and mixed form cataracts, and/or resultant 
lens extraction (LE) in the T2DM and ND subgroups. Unlike many earlier 
investigations, this study considers the association between cataract and T2DM only, 
and not DM in general, as the epidemiological trends for type 1 DM (T1DM) and 
T2DM are different. Our study approach is unique in that it considers the entire 
lifespan and defines cataracts to include early changes as well as visually significant 
ones. Thus, the age of AR cataract onset can be observed in a prevalence function 
generated though logistic regression that considers all ages. This approach also 
allows easier comparison to other studies that vary in the age groups reported. 
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Finally, the prevalence of statin use and any associations between statin use and AR 
cataract prevalence is determined for patients with T2DM and ND.  
 
4.3 METHODS 
The Waterloo Eye Study (WatES) database was developed from a retrospective file 
review of 6397 patient visits from January 2007 to January 2008 at the University of 
Waterloo, School of Optometry. Data was abstracted for several variables for cross-
sectional analysis. Abstraction methods, data quality analysis, study limitations and 
population representation of the database have been detailed in an earlier paper.
28
 
Furthermore, overall cataract prevalence and the modelling technique have been 
reported previously for this data set including a comparison between male and female 
patients.
1
 The abstracted ocular health data in the current investigation included the 
presence of any clinically apparent AR cataract (NS  grade I, LOCS II,
29
 any CC, 
any PSC or any history of related LE) and surgical dates from LE. A report of lens 
opacity in either eye was accepted as a diagnosis. The systemic health information 
included a diagnosis of T1DM or T2DM, and any medication being taken. Patient age 
was electronically calculated in the database from the date of assessment and the 
patients’ birthday, and this information was available for all patient files. 
The repeatability of data abstraction was determined through inter-abstractor 
agreement rates of 425 double-entered clinic files.
28 
As previously reported, Cohen 
Kappa statistic values were high for patient sex and the presence of NS, CC, PSC, 
and LE as was the intra-class coefficient value for patient age.
1
 The Kappa value for 
the presence of DM was very high at 0.99 with less than a 1% disagreement rate 
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between abstractors. The Kappa value was somewhat lower for overall medications 
(K=0.84); however when considered on its own, the inter-abstractor agreement for 
statin use was high at K=0.95 with a disagreement rate of less than 1%. 
Patients with T1DM were excluded from the analysis. The remaining patients 
(n=6336) were separated into subgroups of patients having T2DM or being ND and 
then further sorted into patients having any or no AR lens opacity. The age and sex 
distributions of the T2DM group were compared to provincially available data on 
DM rates in Ontario.
19
 The overall prevalence (%) of any AR cataract was 
determined for T2DM and ND subgroups. Multivariable logistic regression analysis 
was done to determine prevalence probability functions for AR cataract in the two 
subgroups. We have previously shown a sex difference in AR cataracts in this 
population, with being female associated with an increased risk of CC.
1
 Smoking is 
known to be associated with nuclear sclerosis.
8,12,13
 Recently the Malay Study looked 
at the components of metabolic syndrome and their relationship to AR cataracts. 
Besides DM, the presence of hypertension (HTN) was associated with increased 
odds of having cataract.
30
 Therefore, sex, smoking and HTN were also controlled for 
in this analysis. The odds ratio (OR) for a diagnosis of T2DM and AR cataract 
prevalence was calculated. The ages at which there was a 50% prevalence of AR 
cataracts for ND and T2DM patients were determined from these functions.  
The prevalence of NS, CC and PSC was determined separately independent of 
whether they occurred in a mixed-type presentation or as homogeneous opacities. 
There were a significant number of patients with CC or PSC that also had NS. For 
this reason, an insufficient number of patients with CC or PSC only were available to 
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consider only patients with a single type of opacity in our analysis. Instead, we chose 
to do a multivariable logistic regression analysis controlling for the aforementioned 
variables as well as the other lens opacity types when looking at NS, CC and then 
PSC. Patients with monocular LE were categorized by the cataract type in the other 
eye. Patients who had undergone bilateral LE (n= 312) were excluded as it was not 
possible to determine which type of AR cataract existed pre-surgically. For the 
remaining patients (n=6024), OR’s for any association between a diagnosis of T2DM 
and cataract subtype prevalence were calculated. The ages at which they had a 50% 
prevalence of NS or CC or 10% prevalence of PSC were compared for each 
subgroup. 
Next, considering patients over 38 years with AR cataracts, the proportion of total 
AR cataract patients with mixed and homogeneous cataract was compared for 
patients with T2DM and ND. The AR cataract subgroups were sorted into 1) NS 
only, 2) CC only, 3) PSC only, 4) mixed with NS and CC, 5) mixed with NS and 
PSC, 6) mixed with CC and PSC and finally 7) mixed with all three types. 
Categories 4) to 7) were totalled to determine the proportion of each diabetic 
subgroup with mixed cataract.  
The prevalence of LE and odds of having LE in patients with T2DM compared to 
ND was determined. Subsequently, the age at first LE was calculated from patient 
age and surgical dates (nearest year) for patients with any monocular or binocular 
LE. From this, mean ages of first LE were determined for applicable patients with 
T2DM and ND and compared for a significant difference.  
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Finally, the prevalence of reported statin use was determined for the T2DM and ND 
subgroups. A multivariable analysis was performed to control for age, sex, smoking, 
HTN and DM status, to determine any associations between statin use and overall 
AR cataract prevalence and then each AR cataract subtype. Prevalence probability 
functions for AR cataract were determined for each of the following groups: 1) 
T2DM patients not taking statins, 2) T2DM patients taking statins, 3) ND patients 
not taking statins, and 4) ND patients taking statins. 
 
4.3 RESULTS  
There were 452 T2DM, 5884 ND and 61 T1DM patients, representing 7.0%, 91.9% 
and 0.9% of the study population respectively. The mean age for the T2DM 
subgroup was 64.3 ±12.4 (SD) years compared to 40.8 ± 25.4 (SD) years for ND. 
Whereas the ND subgroup had a slightly higher proportion of female patients 
(n=3236 or 55.0%) compared to male patients (n= 2648 or 45.0%), the sex 
distribution of T2DM subgroup was skewed towards more male patients. There were 
only 194 female compared to 258 male T2DM patients, representing 42.9% and 
57.1% of the T2DM group respectively. The Canadian Diabetic Association (CDA) 
used algorithms applied to health care administrative data from 1995 to 1999 to look 
at prevalence rates of diagnosed DM in Ontario and create the Ontario Diabetes 
Database (ODD).  The CDA could not separate T1DM from T2DM from their 
available data, so reported results include all cases of DM.
19
 Figure 4-1 compares the 
age distribution of WatES patients with DM (T1DM and T2DM) to the 1999 ODD 
numbers using their age grouping. The overall rate of DM in people >19 years of age 
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was 10.5% for the WatES database in 2007 and 6.2% for the ODD in 1999. For both 
databases, women in the 20 to 34 year age group had a slightly higher prevalence of 
DM than men, but a lower prevalence in all remaining age groups. However, WatES 
has a lower proportion of patients with DM who are senior than the ODD study 




Figure 4-1. Prevalence of Diabetes Mellitus (DM) as a function of age group 
(% per age group) for males (M) and females (F), in the Waterloo eye study 
2007 (WatES) and the Ontario Diabetes Database 1999 (ODD). 
 
The relatively older WatES T2DM subgroup had 348 of its 452 patients (77.0%) 
with some clinically apparent age-related cataract whereas the proportionately 
younger ND group only had 1882 out of 5887 with age-related cataract (32.0%). 
Figure 4-2 shows the prevalence of AR cataract in the T2DM and ND groups in 
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yearly age groups to control for the age disparity between T2DM and ND patients. 
Prevalence probability functions were determined and also shown in the figure. 
Cataracts occurred earlier in the T2DM subgroup, with the probability of 50% 
prevalence reached by age 53.2 (95% CI, 52.3–54.0) years compared to 57.0 (95% 
CI, 56.7–57.2) in the non-diabetic (3.8 year difference) patients. There was no 
statistically significant difference in the slope value of these two functions, 
indicating that once the prevalence of age-related cataracts begins to rise, the rate of 
increase in prevalence appears similar for the two subgroups. For this population, a 
diagnosis of T2DM was associated with an increased odds of having AR cataracts 
(OR=1.86, 95% CI, 1.34–2.59) across the lifespan when controlling for age, being 
female, smoking and hypertension. 
 
 
Figure 4-2. The prevalence of age-related cataract (AR) in WatES patients with 
type 2 diabetes (T2DM) (n=452) and patients that do not have diabetes (ND) 
(n=5884) over the entire lifespan in yearly age groups. The probability function 




Table 4-1 presents the results from logistic regression analysis for each 
morphological AR cataract subtype. Fifty percent prevalence occurred about four 
years earlier for both NS and CC in T2DM compared to ND patients. As PSC was 
significantly less prevalent, the age of 10% prevalence of PSC is shown which 
occurred close to eight years earlier in the patients with T2DM. After multivariable 
analysis, a diagnosis of T2DM in this study group was associated with increased 
odds of having NS (OR=1.84, 1.32–2.56), CC (OR=1.38, 1.04–1.82) and PSC 
(OR=1.52, 1.04–2.19) compared to ND patients.  
 
Table 4-1. Predicted ages for specified prevalence amounts from multivariable 
logistic regression analysis of each AR cataract subtype. WatES patients were 
grouped as having type 2 diabetes (T2DM) (n=452) or not having diabetes (ND) 
(n=5884). 
Cataract type Prevalence T2DM age (yrs) ND age (yrs) Difference (yrs) 
NS 50% 54.4 58.4 4.0 
CC 50% 75.5 79.8 4.3 
PSC 10% 64.2 71.9 7.7 
 
There were 291 T2DM and 1619 ND AR cataract patients over 38 years of age. 
Figure 4-3 demonstrates an increased proportion of mixed AR cataract in the patients 
with T2DM compared to ND. Whereas 42.3% of AR cataracts in T2DM patients 
over 38 years had a combination of two or more components, only 35.2% of the AR 
cataracts in ND patients over 38 were mixed. Only patients over 38 years of age 




Figure 4-3. Frequency distribution of homongeneous and mixed lens opacities in 
WatES patients with type 2 diabetes (T2DM) and patients that do not have 
diabetes (ND) over 38 yrs with age-related cataract (excluding those with 
bilateral LE). 
 
There were 72 T2DM patients and 345 ND patients who had either monocular or 
binocular LE for AR cataracts. A higher percentage of T2DM patients with AR 
cataracts had already had bilateral LE (16.0%) compared to the ND cataract group 
(13.0%). Also, the T2DM subgroup had their first LE at a mean age of 70.3 yrs. 
compared to 72.9 yrs for the ND subgroup (2.6 year difference, p<0.05, t-test). There 
were four ND patients with unknown surgical dates and they were excluded from 
this analysis. Controlling for the same variables as before, the T2DM subgroup had 
an increased odds (OR=1.60, 1.15–2.22) of having LE compared to the ND 
subgroup.  
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The mean age of patients taking statins was 68.5 years (± 11.1). Statin use increased 
with age such that 0.4% of WatES patients under 39 years of age, 9.2% of patients 
between 39 and 59, and 30.5 % of patients over 60 were taking statins. Considering 
diabetic status, statin use was reported in 56% of T2DM patients but only 16% of 
ND patients over 38 years. As shown in Table 4-2, after controlling for age, sex, 
smoking, HTN and diabetic status, statin use was significantly associated with AR 
cataract (OR=1.57, 1.15–2.13), NS (OR=1.48, 1.09–2.00) and PSC (OR=1.48, 1.07–
2.04) but not CC (OR= 1.02, 0.80–1.30). Interestingly, PSC was no longer 
significantly associated with T2DM when controlling for statin use. CC was still 
associated with being female (OR=1.59, 1.30-1.94) and in this analysis, HTN 
(OR=1.24, 1.00-1.53). Agreeing with results from other studies, NS was associated 
with smoking (OR= 1.62, 1.08-2.42).  
 
Table 4-2. Odds ratio (95% CI) for AR cataracts and cataract subtypes in 
WatES patients using multivariable logistic regression analysis (patients with 
type 1 diabetes mellitius were excluded). 
 






















































As shown in Figure 4-4, the probability of AR cataract in patients who use statins 
reached 50% at age 51.7 and 54.9 years in T2DM and ND patients respectively. In 
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patients who did not use statins, it was later at 55.1 and 57.3 years for T2DM and 
ND patients respectively.  
 
 
Figure 4-4. Comparsion of age-related cataract using logistic regression 
analysis in WatES in four patient groups: having type 2 diabetes (T2DM) 
and using statins, type 2 diabetes and not using statins, no diabetes (ND) 
and using statins, and no diabetes and not using statins.  
 
4.4 DISCUSSION 
WatES is a cross-sectional database and therefore cannot determine causation of 
disease. Retrospective file reviews can identify associations between factors and are 
useful for directing further study. In this clinic population, a strong association 
between age and T2DM was confirmed, as the age distribution of these patients with 
DM was skewed toward the senior years compared to ND patients. It is also 
important to identify potential biases and to recognize what type of population your 
sample represents.  
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Previously, the age distribution of the WatES clinic population was shown to be 
comparable to that from a study of representative optometric practices across 
Canada.
5,28
 This investigation shows that the age and sex distribution of WatES 
patients with DM approximated the provincial distributions given by the ODD. The 
CDA reports that the age and sex-adjusted prevalence of DM per 100 Ontarians over 
19 years of age rose from 4.72% in 1995 to 6.19% in 1999 (0.29% increase/year on 
average).
19
 If the increasing trend continued, one could expect that in 2007 the 
provincial prevalence of DM would have been around 8.51% which approaches the 
10.48 % overall rate of DM found in the WatES.  
Patients with DM are encouraged to get routine eye assessments because of the 
increased risk of ocular disease in DM, and therefore, we could expect a clinical eye 
care population to have a somewhat higher percentage of patients with DM than the 
general population.
8
 The fact that vision assessment costs are covered by the 
provincial health insurance plan for patients with DM but not non-diabetics between 
the ages 20 to 64 years of age, could also increase the prevalence of DM in the 
WatES clinic population. This may explain the slightly higher percentage of 35–64 
year old WatES patients with DM compared to ODD. However, WatES also had a 
lower percentage of patients with DM over 65 years of age compared to ODD. It is 
possible that proportionately more mature patients with DM are exclusively under 
ophthalmologic care for advanced disease or are in residential care where they 
cannot access optometric care as readily.
31
 We relied on patient reporting for a 
diagnosis of DM, unlike other studies that utilized glycosylated haemoglobin (GHb) 
testing. This may result in a less reliable number of patients with DM in this study. 
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However, Leske et al.
32
 in the Barbados Eye Study (BES) also relied on patient 
reports of diabetes. They compared results using GHb measurements taken for the 
study and found consistency in associations for cataracts whether a reported diabetic 
history or GHb measurements were used. Finally, selection bias in clinic-based 
population studies can occur as patients with symptoms from maturing cataracts may 
be more likely to seek out vision care than those without. However, our inclusion of 
pre-symptomatic levels of cataract helps minimize this bias.
 
In this study, T2DM was found to be significantly associated with AR cataract. DM 
has been previously shown to be a risk factor for AR cataracts but the strength of this 
association has varied among studies.
11–17
 Comparison to other studies can be 
hindered by the differing cataract grading scales and the age-groups chosen by 
various investigators. Therefore, investigators must conduct literature reviews 
carefully. In 1998, the BES looked at the relationship between DM and the 
prevalence of cataract using the LOCS II scale. They reported that a history of DM 
was related to any age-related lens changes (including lens extraction) in their 4313 
patients between 40 and 84 years of age (OR=1.89; 95% CI: 1.52–2.34).
32
 As we 
have generated an AR cataract prevalence function over the entire lifespan, we can 
extract WatES prevalence values for any specified age group. Considering patients 
40 to 84 years only, comparable AR cataract prevalence values to BES are found 
(OR=2.00, 1.44–2.78).
 
In addition to overall AR cataract, T2DM was associated with all three morphological 
cataract subtypes in this population when statins were not considered. However, when 
controlling for statin use, PSC was no longer associated with T2DM. Previous studies 
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have varied on which morphological types are at greater risk of developing in patients 
with DM, but CC and/or PSC are generally identified.
11–13,15, 30,32
 Fewer studies have 
found DM to be a risk factor for NS development. Klein et al.
16
 in their five year follow 
up of the Beaver Dam Eye Study cohort (n=3684) did find that increased levels of GHb 
were shown to be associated with increased risk of NS and CC. Similarly, at the 10 year 
follow up of the Blue Mountain Eye Study, Tan et al.
14
 found that baseline DM 
predicted NS and impaired fasting glucose predicted CC when controlling for age and 
sex. However, most studies looked at much higher grades of nuclear sclerosis than 
WatES resulting in weak associations between DM and NS. NS at these levels tends to 
occur at fairly advanced ages where the prevalence of severe DM also diminishes due 
to increased mortality in patients with DM.
33
 Our inclusion of all levels of cataract is 
less specific to visual significance but is more sensitive to differences in onset and 
prevalence of cataracts in patients with DM.  
A higher rate and earlier age of AR cataract surgery was also found for patients with 
DM in this population. Presumably, an increased amount of PSC would translate into 
an increased risk of LE, as it is centrally placed causing debilitating visual symptoms 
fairly quickly.
34
 However, differences in mean age of surgery may reflect differences 
in surgical criteria by ophthalmologists. Historically, surgeons may have had a 
higher treatment threshold for cataract removal in patients with DM as they are 
known to have poorer visual outcomes than non-diabetics which include an 
increased risk of complications.
35
 On the other hand, Pollreisz et al.
36
 report that 
there has been a recent shift towards earlier cataract extraction in patients with DM 
so lens opacity does not prohibit detailed fundus examination.  
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Our data cannot suggest causation of AR cataract with statin use but an undeniable 
association was found in this population after controlling for age, sex and diabetic 
status. In early clinical trials with statins, researchers did not report significant 
lenticular changes in patients observed for relatively short periods of less than five 
years.
23–26,37,38
 Several animal studies have clearly shown a correlation between 
cataract development and chronic statin treatment, although drug dosages have been 
generally higher than the clinical levels given to humans.
39–41
 A few human 
population studies have even suggested a protective effect with statins use and 
cataract risk,
42–44 
hypothesizing an anti-inflammatory/antioxidant mechanism for the 
effect.
44
 However, Smeeth et al.
45
 point out that lens opacities are a gradual process 
making incident cataracts rare and that many human studies involving statins and 
cataracts lack adequate power as a result. Cenedella
46
 suggests that the long term 
impact of statin use requires study periods of between10 to 20 years. Beri et al.
47
 
published a literature review of studies between 1950 and 2008 involving the non-
arteroprotective effects of statins. They concluded there was inadequate and 
conflicting evidence for statin benefit in any condition (including cataract) beyond 
hyperlipidemia and atherosclerosis. Recently, Hippilsley-Cox and Coupland
27
 looked 
at data for over 2 million patients (ages 30-84) in a prospective cohort study 
involving 368 general practices in the UK. Over 10% of the patients were new statin 
users and the effects of statin type, dose and duration of use were estimated by Cox 
proportional hazard models. Refuting earlier findings, statin use was associated with 
an increased risk of cataract.  
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The bio-plausibility of these results lies in the fact that the crystalline lens membrane 
requires high cholesterol for proper epithelial cell development and lens 
transparency. Increased cataract formation has been seen in both animals and 
humans with hereditary cholesterol deficiency
46,48 
and the risk exists that statins can 
inhibit cholesterol biosynthesis in the human lens.  
Our study benefits from the statistical power associated with its large sample size. As 
this is a later study, there also could be more patients with longer exposure to statin 
use than earlier population studies when statins were first being recommended. 
Further study is warranted to recommend close monitoring of crystalline lenses in 
patients benefiting from statins, especially those with T2DM.  
 
4.5 CONCLUSIONS 
Given the aging population and the expected increase in the number of people 
affected by age-related cataract, it is important to identify associated risk factors. In 
this Canadian clinic population, having a diagnosis of T2DM was significantly 
associated with an increased prevalence of age-related cataract overall and an earlier 
onset of NS and CC when statin use is considered. This resulted in a greater 
proportion of mixed cataract development in this subgroup and an earlier mean age 
of surgical intervention. Furthermore, in this population, reported statin use was 
strongly associated with an earlier development of NS and increased risk of PSC. 
This information can serve Canadian public health efforts to educate people on the 
risks of DM and promote efforts to curtail current DM prevalence trends. 
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Chapter 5 
General Discussion and Conclusions 
 
This investigation demonstrated how information contained in optometric files at a 
large clinic can provide epidemiological data. The risk of interpretational bias 
existed as the file information was coming to the researchers indirectly. However, 
repeatability analysis done on double-entered files and missing data calculations 
verified that the study variables could be reliably abstracted and were without 
significant bias from file omissions. Like other cross-sectional studies, this research 
described population demographics and the distribution patterns of selected variables 
while examining associations between these variables without the concern of subject 
drop out as in cohort studies.
1
 Over 6000 patient visits contributed to the information 
in the WatES database providing significant statistical power for all analysis. The 
sex and age distribution of this clinic population differed in some aspects compared 
to that of available statistics on the general Canadian population.
2
 This clinic 
population was not a randomly selected group and was subject to bias in terms the 
type of individuals seeking out eye care.  However, there was sufficient similarity to 
the demographic profile of Canadian optometric practices in the Robinson study, for 
clinicians to estimate the chance of AR lens opacity within their patients with these 
data. By using the criterion of clinically apparent AR cataract as opposed to the more 
commonly chosen advanced levels of lens opacity, yearly prevalence levels for 
overall AR cataract approached 100% by the late seventies. Earlier investigations 
reported on the prevalence of AR cataract in discreet varying age groups making 
 71 
study comparisons challenging. The WatES database included data for all yearly age 
groups, and as such the onset of overall AR cataract prevalence was demonstrated as 
patients reached their late thirties with a sigmoid increase in cataract frequency after 
that. The probability of AR cataract function, generated through logistic regression 
analysis allowed predictive prevalence levels at a chosen patient age. Thus, in a 
similar population, it is likely that half the patients in their mid-fifties would have 
some AR lens opacity.  Early to late NS was the most prevalent lens opacity subtype 
occurring in 28.8% of the population, and contributed significantly to the probability 
function. The prevalence of CC was 9.9% in this population followed by PSC at 
3.6% which are comparable proportions to a study with similar cataract definitions 
once age matched.
4
  Being female was associated with CC specifically. Despite any 
differences in our health care system, this Canadian data yielded a similar age of first 
lens extraction at 72 years compared to European studies.
5,6
  Again, consistent with 
these studies, women had a greater overall rate of bilateral lens extraction but 
approximately a three year later age of first lens extraction compared to men. 
AR cataracts, T2DM and statin use were found to be prevalent conditions, especially 
after 38 years of age, which made them more appropriate factors for cross-sectional 
analysis than rarer conditions.
1
 Previous work clearly demonstrated associations 
between diabetes mellitus (DM) and AR cataracts, and this study confirmed a similar 
association existed when T2DM is considered independently (without type 1 DM) 
while controlling for age, being female, smoking and hypertension. The impact of 
this association has not been quantified in the literature in terms of age differences in 
cataract development between patients with T2DM and those without diabetes. 
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Applying our probability of AR cataract model to T2DM and non-diabetic 
subgroups,  the age of 50% probability of AR cataract in patients with T2DM was 
close to four years earlier than patients without DM. As with other studies, 
significantly more CC was seen in the T2DM subgroup compared to those without 
DM.
7,8,9,10
  However, a clear association with NS and T2DM in this investigation 
demonstrated how the degree of opacity chosen in these studies can effect 
associations. The consequences of NS, CC and PSC being associated with T2DM in 
this population included 7% more mixed cataracts and almost a three year earlier age 
of first lens extraction in patients with T2DM compared to patients without DM. 
 
Reported statin use was almost 3.5 times higher in patients with T2DM than patients 
without DM over 38 years of age. Statin use was significantly associated with AR 
cataract such that the probability of cataract for patients with T2DM who did not use 
statins was similar to patients without DM who did use statins. Statin use was 
specifically associated with NS and PSC in this population, which has not found to 
have been reported previously in the literature. One of the most compelling findings 
was that PSC, long associated with DM, was no longer significantly associated with 
T2DM when controlling for statin use. The cross-sectional nature and limitations in 
available file information did not allow analysis of statin type, dosage, or duration of 
use and their relationships to lens opacity. However, the strong association found 
between statin use and AR cataract in this study, validates the need for a more 
complex study design to investigate these more specific aspects of statin use.  Also, 
cross-sectional studies such as this often become the baseline for future cohort 
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studies on associations of interest.
1
 It is likely that some of the associations found in 
this study but not in previous investigations, reflect the additional years of potential 
statin use compared to earlier studies. Statins are intended for long-term use and 
Neutal et al, in their report on statin use in Canada, found that approximately 75% of 
users continue to take statins for at least two years once they have started.
11
 It is 
important to point out that statin use does not necessary reflect pre-medication 
dyslipidemia in this population as use of the pharmaceutical has moved away from 
only patients with high cholesterol to be recommended for all patients with heart 
disease and diabetes.
11
 A future study that controls for both statin use and blood 
cholesterol levels and looks at AR cataract frequency while controlling for sex, 
T2DM, smoking and hypertension would be particularly valuable.  Given the high 
cost of lens extraction to the health care system, further work on the impact of statin 
use on cataract surgery rates is also recommended.  
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Appendix  
Additional Table for Chapter 2 
 
Table 2-6 Distribution of Waterloo Vision Study patients in five-year 
increments 
Age group Number of patients % study population 
<5 460 7.2 
5-9 465 7.3 
10-14 373 5.8 
15-19 350 5.5 
20-24 474 7.4 
25-29 252 3.9 
30-34 228 3.6 
35-39 244 3.8 
40-44 337 5.3 
45-49 431 6.7 
50-54 395 6.2 
55-59 398 6.2 
60-64 432 6.8 
65-69 444 6.9 
70-74 404 6.3 
75-79 362 5.7 
80-84 242 3.8 
85+ 106 1.7 
Total 6397 100 
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Additional Figures for Chapter 2 
 
 
Figure 2-3 Distribution of WatES patients and representative optometric 






Figure 2-4 Age distribution of male and female WatES patients in five year 
increments.  
 
